

November 7, 2013
For Immediate Release
Contact: Dolly Koltchev, Ph.D.
Program Director
dkoltchev@biopharmaresearchcouncil.org
732-933-9473 x 807

Best Practices IV: Preclinical Outsourcing November 20, 2013 at the Jersey Shore Lunch and Program with Simulcast Webinar

(Long Branch, NJ) The BioPharma Research Council (BRC) will present its Best Practices IV: Preclinical Outsourcing on November 20, 2013, at the Conference Center at Ocean Place in Long Branch, NJ, or via Webinar.

The program will evaluate the effective use of contract research organizations (CROs) by academia, industry and nonprofit entities to develop innovative therapeutics.

"As biopharmaceuticals have developed into a 50 billion dollar a year industry, preclinical outsourcing has become a common practice. Companies have become reliant on outside, specialized services to supplement their internal research and development," says Program Director Dolly Koltchev, PhD. "Our speakers will present their most effective practices in preclinical outsourcing for feeding drug development pipelines, building strong relationships that lead to advancements in curing human disease."

The topics that will be covered by the presenters provide thoughtful insight into current industry trends, as well as ideas to increase the efficiency and productivity of the preclinical process.; utilizing modern technology to cut the costs and risks of preclinical research are underlying themes found in the presentations.

Among the presenters are Rachel Lane, Ph.D., Assistant Director, Scientific Affairs, at Alzheimer's Drug Discovery Foundation (ADDF); Kuldip Dave, Ph.D., Senior Associate Director, Research Programs, at The Michael J. Fox Foundation for Parkinson's Research (MJFF); Patrick M. Dentinger, President & CEO, Absorption Systems; and Christopher J. Kemper, Ph.D., Principal, PharmaNavigators, LLC.

For more information and registration, please visit <u>www.biopharmaresearchcouncil.org</u> or call Joanne Gere, Executive Director, at 732-403-3137.